Patients with cystic fibrosis (CF) have low cholesterol absorption and, despite enhanced endogenous biosynthesis, low serum cholesterol. Herein, we investigated cholesterol metabolism in a murine CF model in comparison to wild type (WT) testing serum and liver surrogate biomarkers together with the hepatic expression of genes involved in cholesterol metabolism. CF mice display lower sterols absorption and increased endogenous biosynthesis.
Introduction
Cystic fibrosis (CF) is a life-limiting, autosomal recessive genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. These mutations lead to a defective transport of chloride and other ions through the respiratory, biliary, gastrointestinal and reproductive epithelia bringing on the secretion of thick mucus (Cantin et al, 2015) . In particular, at pancreatic level, the mucus represents an obstacle to the secretion of pancreatic enzymes in the intestine causing pancreatic insufficiency (PI) with an altered digestion (Gibson-Corley et al, 2016; Peretti et al, 2005) and absorption of lipids (Turck et al, 2016) .
In a preliminary study (Gelzo et al, 2016) , we evaluated cholesterol metabolism in patients with CF by analyzing surrogate biomarkers (Miettinen et al, 2011) . Specifically, we determined the plasma levels of campesterol and β-sitosterol (phytosterols) that are biomarkers of intestinal lipid absorption and lathosterol, as a marker of hepatic de novo cholesterol biosynthesis. The study showed reduced intestinal absorption of sterols together with an increase of endogenous cholesterol biosynthesis in patients with CF compared to unaffected subjects. But, despite the increased liver synthesis, plasma cholesterol levels in patients with CF were lower (Gelzo et al, 2016) . This may be due to the partial retention of endogenous cholesterol in hepatocytes, due to a defective exocytosis of cholesterol in patients with CF, as previously demonstrated in CF cell lines and in animal tissues (White et al, 2007) .
Thus, we observed that CF patients with PI had a significantly reduced absorption of cholesterol and vitamin E as compared to CF patients with pancreatic sufficiency (PS) and to healthy controls suggesting that the supplementation of pancreatic enzymes used in all CF patients with PI was not sufficient to permit a normal digestion of lipids (unpublished results).
This could depend on the small amount of cholesterol esterase in the supplementation therapy (Walters et al, 2001 ) and on the reduced synthesis, secretion (Russell, 2003) and reabsorption of bile salts (van de Peppel et al, 2019) that occur in patients with CF.
Therefore, the aims of the present study were: i) to investigate cholesterol metabolism in CF compared to wild type (WT) mice by determining serum and liver levels of surrogate biomarkers together with the hepatic expression of genes involved in biosynthesis and catabolism of cholesterol; ii) to evaluate the effects of cholesterol supplementation on cholesterol metabolism in CF and WT mice.
Results

Wild type mice fed with and without cholesterol-supplemented diet
We compared 4 WT mice that received the cholesterol-supplemented diet with 3 WT mice that received a diet with no cholesterol supplementation. As shown in Table 1A , supplemented mice show significantly lower levels of serum phytosterols (7.6 fold) and liver lathosterol (7.6 fold) and significantly higher levels of liver cholesterol (6.2 fold) and cholestanol (4.2 fold). Serum cholesterol was significantly higher (1.3 fold). Furthermore, as shown in Table 1B , WT mice fed with cholesterol supplementation have significantly lower levels of liver LDLR (2.5 fold) and HMG-CoAR (2.2 fold) mRNA, while ACAT2 and CYP7A1 mRNA levels resulted significantly higher (2.9 and 6.0 fold, respectively). Finally, liver mRNA levels of TNFα were higher although not significantly (Figure 1 ).
CF and WT mice fed without cholesterol-supplemented diet
We compared 3 CF mice with 3 WT mice both fed with no cholesterol-supplemented diet. As shown in Table 2A , CF mice have significantly lower levels of serum phytosterols (2.0 fold), significantly higher levels of liver lathosterol (3.1 fold) and cholesterol (1.2 fold), while liver cholestanol was not significantly different. Serum cholesterol was lower (although not significantly) as compared to WT mice. Furthermore, as shown in Table 2B , CF mice have higher levels of liver LDLR and ACAT2 (although not significantly), while mRNA levels of HMG-CoAR (18.0 fold) and CYP7A1 (16.3 fold) mRNA were significantly higher as compared to WT mice. Finally, liver mRNA levels of TNFα were higher, although not significantly in CF mice ( Figure 1 ).
CF mice fed with cholesterol-supplemented diet
We compared 4 CF mice that received a diet with cholesterol supplementation with either the 4 WT mice that received a diet with cholesterol supplementation and with the 3 CF mice that received a diet with no cholesterol supplementation. As shown in Table 3A , comparing the CF with WT mice both with cholesterol supplemented diet, we observed: i) significantly higher levels of serum phytosterols (2.0 folds) and liver lathosterol (22.0 fold);
ii) significantly lower levels of both serum (1.3 fold) and liver cholesterol (4.3 fold) together with significantly lower liver cholestanol (3.4 fold). Furthermore, as shown in Table 3B , CF mice fed with cholesterol supplementation have significantly higher levels of liver LDLR (4.7 fold), HMG-CoAR (41.2 fold) and CYP7A1 (5.3 fold) mRNA levels as compared to WT mice fed with cholesterol supplementation, while the liver mRNA levels of ACAT2 were not significantly different (Table 3B ). Finally, liver mRNA levels of TNFα were higher, although not significantly ( Figure 1 ). Table 3A and B, comparing the CF mice with supplemented diet to CF mice with no supplemented diet, we observed that all the parameters resulted not significantly different, with the exception of serum phytosterols that were significantly lower in CF mice supplemented (2.0 fold), liver cholesterol (1.3 fold) and liver mRNA levels of TNFα (5.0 fold) that were significantly higher ( Figure 1 ).
Finally, as shown in
Discussion
Our study demonstrates that the cholesterol supplementation in WT mice results in a series of biochemical changes similar to those physiologically observed in humans (Hu et al, 2010) , in agreement with previous studies (Repa et al, 2004; Schwarz et al, 2001) . In fact, the supplementation causes: i) enhanced intestinal absorption of cholesterol; ii) reduction of serum phytosterol for a competitive mechanism of intestinal absorption with cholesterol (Gylling & Simonen, 2015) ; iii) the inhibition of LDLR expression due to the increased liver uptake of cholesterol (Hu et al, 2010; Goldstein & Brown, 1990) ; iv) the inhibition of endogenous biosynthesis of cholesterol, supported by lower liver expression of HMG-CoAR (Hu et al, 2010; Goldstein & Brown, 1990 ) and the consequent decreased liver levels of lathosterol; and v) the activation of liver cholesterol catabolism supported by the enhanced expression of ACAT2 and CYP7A1 that stimulate the esterification of cholesterol and the synthesis of bile salts respectively, and increased liver cholestanol, a catabolic product of acidic pathway of bile salts (Russell, 2003) .
Cystic fibrosis mice compared to WT, both fed with no cholesterol-supplemented diet, display a series of metabolic alterations some of which are similar to those observed in patients with CF (Gelzo et al, 2016) : i) lower intestinal absorption of sterols, supported by the lower levels of serum phytosterols; ii) increased endogenous biosynthesis of cholesterol, confirmed by a very high expression of liver HMG-CoAR and by higher concentrations of liver lathosterol. Nevertheless, the enhanced synthesis of cholesterol is unable to correct the lower levels of serum cholesterol observed in CF as compared to WT mice. These data confirm that in CF mice the liver mechanisms of synthesis/excretion of cholesterol are impaired, as it has been demonstrated in CF cell models and in tissues from CF mice (Fang et al, 2010; White et al, 2004) . That study reported the enhanced de novo synthesis of cholesterol, followed by its accumulation at endo-lysosomal level due to a block in the translocation to the Golgi and endoplasmic reticulum (ER). They postulated that the accumulation was due to a generalized mechanism caused by misfolded membrane proteins that escape ER quality control and impact on lipid homeostasis (Gentzsch et al, 2007) . The lack of cholesterol provision to the ER is followed by the activation of sterol regulatory element-binding protein that enhances the endogenous synthesis of cholesterol (White et al, 2007) . We confirm that in CF mice liver there is an enhanced biosynthesis of endogenous cholesterol due to the lack of inhibition of HMGCoAR (Hu et al, 2010; Goldstein & Brown, 1990) , which could be due to the lack of unidentified endogenous factors and causes the accumulation of cholesterol in the liver. Despite this, we observed a lack of inhibition of LDLR expression in the CF liver that further contributes to accumulate cholesterol. Such accumulation triggers inflammation, as it is demonstrated by the higher levels of TNFα expression (Yang & Seki, 2015) that we observed in CF as compared to the WT mice liver.
Interestingly, the liver of CF mice enhances the expression of ACAT2, the enzyme that esterifies cholesterol before its secretion (Hu et al, 2010; Goldstein & Brown, 1990) , but this activation is not followed by a significant release of cholesterol in blood. Similarly, the liver of CF mice expresses very high levels of CYP7A1, the key enzyme in the catabolism of cholesterol to bile salt (Russell, 2003) , but also such metabolism may be impaired, since the levels of liver cholestanol, an intermediate of bile salt synthesis (Russell, 2003) , are similar to those observed in WT mice.
The cholesterol supplementation in CF mice causes an increase of serum cholesterol (even if less significant of that observed in supplemented WT) and a significant reduction of serum phytosterols (about 50% less) as compared to CF mice with no supplementation, indicating that the supplementation favors some absorption of cholesterol in CF mice.
However, the supplementation promotes a mild increase (+ 35%) of cholesterol in the liver, compared to CF mice with no supplementation, which is due to the alterations above mentioned observed in the CF liver increasing further the inflammatory reaction, supported by the considerable expression of TNFα.
All these results show that in CF mice there is a vicious circle, in which the altered synthesis and secretion of biliary salts contribute to reduce cholesterol digestion and absorption; as a consequence there is the enhanced liver biosynthesis of cholesterol that accumulates in the cell triggering inflammation that involves small bile ducts further impairing the synthesis and release of biliary salts. These results have a translational impact on cholesterol metabolism in patients with CF that mostly show low levels of serum cholesterol with a myriad of clinical consequences (Segoviano-Mendoza et al, 2018; Elam, 1995) . In order to break the vicious circle of CF cholesterol metabolism it would be necessary to act in two directions: i) enhance the cholesterol supplementation with the diet, associated to an adequate amount of bile salts and pancreatic cholesterol esterase for its digestion; ii) modulate the endogenous synthesis in order to reduce cholesterol accumulation in the liver and the consequent inflammation. In this context, the analysis of surrogate markers of cholesterol metabolism may help to define and monitor the individual therapy in patients with CF. week old CF (n. 4) and WT (n. 4) mice, were fed with CF diet (Charles River V1124-70) enriched of linoleic acid and vitamin E for 10 weeks and then they were fed with a diet supplemented of cholesterol (1% wt/wt) for 4 weeks (Envigo TD02026). At the end of the last daily treatment, mice were anesthetized with Avertin (tribromoethanol, 250 mg/kg, Sigma-Aldrich, T48402) and then killed. Blood and liver samples were collected and stored at -80 °C (vanDoornick et al, 1995) .
Materials and methods
Mice and treatments
All the procedures in mice were approved by the local Ethics Committee for Animal Welfare (IACUC No. 849) and were carried out in strict respect of European and National regulations for animal use in research (2010/63 UE).
Sterol profile analysis
For the analysis of serum sterols, blood samples without anticoagulant/additive were collected and stored in plastic tubes at -80°C suddenly after collection. Before sterols extraction, each blood sample was centrifuged at 14000 rpm for 10 min at 4°C and 100 μL of supernatant (hemolyzed serum) was collected and placed in a pyrex tube. To precipitate the hemoglobin, 1.7 mL of cool ethanol was added to the sample, vigorously mixed and incubated in ice for 15 8 min. The sample was then centrifuged at 3000 rpm for 25 min and the supernatant was transferred in a second pyrex tube for the sterols extraction performed as previously described (Gelzo et al, 2016; Corso et al, 2011) . Briefly, the sample was mixed with 40 μg of 5αcholestane (internal standard) and hydrolyzed by incubation in 1N potassium hydroxide ethanolic solution at 80°C for 1 hour. The sterols were then extracted by hexane and derivatized by BSTFA and pyridine, dried under nitrogen, and dissolved in 100 μL of dichloromethane. For qualitative sterols analysis, 1 μL of solution was injected in a gas chromatograph coupled with a mass spectrometer (GC-MS; GC 7890 A/MD 5975C, Agilent Technologies, Santa Clara, CA, USA) in scan mode from m/z 50 to 500. While, quantitative analysis was carried out by injecting 1 μL of solution in a gas chromatograph coupled with a flame ionization detector (GC-FID; HP-5890, Agilent Technologies). Both instrumentations were equipped with Elite-5MS capillary column (PerkinElmer, USA).
For the analysis of sterols in the liver, the tissue samples were first weighed and the homogenates were subsequently prepared as follows. The liver tissue was placed in a clean plastic vial with 400-800 μL of distilled water, based on the weight of the tissue, and 
RNA isolation, qRT-PCR
We analyzed by qRT-PCR the levels of expression of the following genes: low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoAR), acyl CoA:cholesterol acyl transferase 2 (ACAT2), cytochrome P450 7A1 (CYP7A1), tumor necrosis factor alpha (TNFα).
Total RNA was extracted from mouse liver tissue using TriZol (Invitrogen, Waltham, MA, USA) according to the manufacturer's instructions and genomic DNA was removed by treating with DNAse enzyme. RNA concentration and purity were measured using NanoDrop 9 2000 (Thermo Scientific). RNA (1 μg) was converted to cDNA by reverse transcription using iScript cDNA synthesis kit (Bio-Rad).
qRT-PCR was performed using iQ SYBR Green Supermix (Bio-Rad) and the ABI 7900 HT Real Time PCR System (Applied Biosystems). The qRT-PCR results were normalized on expression levels of β-2-microglobulin, used as internal reference.
Statistical analysis
Data were reported as mean and standard deviation. Comparisons between two groups were performed by T-test. The significance was accepted at the level of p < 0.05. Error bars correspond to standard error.
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